Theravance Biopharma, Inc. (TBPH) Operating Margin
- Operating margin · 12 months: Value -4.03%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4.03% | Operating income / revenue. Period ending 2026-06-30. $-4.20M ÷ $104.31M × 100 ≈ -4.03% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -4.20M USD | Operating Income (Loss) |
| Revenue | 104.31M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 26.01M USD | Research and Development Expense |
| Selling, general and administration | 68.75M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-4.20M | $104.31M | (m) | $26.01M | $68.75M | -4.03% |
| 2026-03-31 | $1.35M | $109.78M | (m) | $31.79M | $73.00M | 1.23% |
| 2025-12-31 | $-3.60M | $107.46M | (m) | $37.41M | $73.65M | -3.35% |
| 2025-09-30 | $-32.81M | $80.33M | (m) | $39.51M | $73.63M | -40.85% |
| 2025-06-30 | $-37.20M | $77.20M | (m) | $40.66M | $72.18M | -48.18% |
| 2025-03-31 | $-50.18M | $65.27M | (m) | $40.13M | $70.80M | -76.88% |
| 2024-12-31 | $-46.95M | $64.38M | (m) | $37.64M | $69.17M | -72.92% |
| 2024-09-30 | $-43.99M | $63.19M | (m) | $36.50M | $66.17M | -69.61% |
| 2024-06-30 | $-41.91M | $62.02M | (m) | $35.55M | $65.43M | -67.58% |
| 2024-03-31 | $-42.33M | $61.51M | (m) | $35.02M | $67.65M | -68.82% |
| 2023-12-31 | $-56.03M | $57.42M | (m) | $40.62M | $70.09M | -97.58% |
| 2023-09-30 | $-67.23M | $54.51M | (m) | $47.66M | $71.33M | -123.33% |
| 2023-06-30 | $-72.67M | $51.27M | (m) | $49.21M | $71.47M | -141.75% |
| 2023-03-31 | $-79.65M | $48.57M | (m) | $54.71M | $68.41M | -163.99% |
| 2022-12-31 | $-91.96M | $51.35M | (m) | $63.39M | $67.07M | -179.09% |
| 2022-09-30 | $-130.69M | $51.64M | (m) | $79.92M | $72.62M | -253.07% |
| 2022-06-30 | $-175.16M | $52.39M | (m) | $113.79M | $77.64M | -334.37% |
| 2022-03-31 | $-212.39M | $54.25M | (m) | $149.31M | $87.87M | -391.51% |
| 2021-12-31 | $-257.78M | $55.31M | (m) | $193.66M | $99.30M | -466.06% |
| 2021-09-30 | $-278.11M | $59.09M | (m) | $227.60M | $107.83M | -470.61% |
| 2021-06-30 | $-301.11M | $64.16M | (m) | $251.23M | $114.04M | -469.32% |
| 2021-03-31 | $-309.17M | $66.25M | (m) | $262.54M | $112.89M | -466.66% |
| 2020-12-31 | $-297.76M | $71.86M | (m) | $260.95M | $108.66M | -414.37% |
| 2020-09-30 | $-291.84M | $82.63M | (m) | $262.81M | $111.65M | -353.20% |
| 2020-06-30 | $-280.43M | $76.80M | (m) | $247.45M | $109.77M | -365.16% |
| 2020-03-31 | $-250.72M | $87.94M | (m) | $231.44M | $107.22M | -285.12% |
| 2019-12-31 | $-251.91M | $73.41M | (m) | $219.25M | $106.08M | -343.14% |
| 2019-09-30 | $-243.96M | $59.65M | (m) | $204.49M | $98.49M | -408.98% |
| 2019-06-30 | $-241.21M | $60.06M | (m) | $205.18M | $94.76M | -401.60% |
| 2019-03-31 | $-247.44M | $57.39M | (m) | $207.40M | $97.54M | -431.16% |
| 2018-12-31 | $-238.75M | $60.37M | (m) | $201.35M | $97.06M | -395.48% |
| 2018-09-30 | $-255.31M | $49.15M | (m) | $200.13M | $101.12M | -519.46% |
| 2018-06-30 | $-249.85M | $40.59M | (m) | $186.78M | $100.18M | -615.63% |
| 2018-03-31 | $-266.27M | $20.62M | (m) | $181.09M | $99.51M | -1291.44% |
| 2017-12-31 | $-260.12M | $15.39M | (m) | $173.89M | $95.59M | -1690.65% |
| 2017-09-30 | $-238.78M | $16.56M | (m) | $164.85M | $86.44M | -1441.65% |
| 2017-06-30 | $-215.28M | $31.36M | (m) | $157.46M | $85.78M | -686.40% |
| 2017-03-31 | $-197.65M | $33.33M | (m) | $146.60M | $81.70M | -593.11% |
| 2016-12-31 | $-180.47M | $48.65M | (m) | $141.71M | $84.51M | -370.96% |
| 2016-09-30 | $-178.41M | $46.85M | (m) | $132.10M | $88.21M | -380.81% |
| 2016-06-30 | $-188.01M | $38.47M | (m) | $130.52M | $90.77M | -488.69% |
| 2016-03-31 | $-185.80M | $40.13M | (m) | $128.82M | $92.05M | -462.95% |
| 2015-12-31 | $-181.90M | $42.13M | (m) | $129.16M | $90.20M | -431.80% |
| 2015-09-30 | $-191.88M | $39.67M | (m) | $138.96M | $87.91M | -483.73% |
| 2015-06-30 | $-198.84M | $35.30M | (m) | $146.91M | $82.77M | -563.23% |
| 2015-03-31 | $-210.26M | $31.14M | (m) | $162.82M | $74.34M | -675.12% |
| 2014-12-31 | $-232.54M | $11.69M | (m) | $168.52M | $71.65M | -1989.55% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-156.28M | $226.00K | (m) | $120.58M | $35.93M | -69152.21% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-9.57M | $130.15M | (m) | $114.00M | $25.73M | -7.36% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |